Neonatal Abstinence Syndrome Clinical Trial
Official title:
Evaluation of Efficacy of Methadone Versus Morphine for Treatment of Neonatal Abstinence Syndrome (NAS).
Hypothesis is that the effectiveness of opiate treatment with morphine will result in shorter duration of opiate medication treatment and fewer infants treated with a second drug.
The purpose is to compare treatment of NAS with two different initial medications with
primary outcome of (1) reducing the duration of opiate medication treatment and (2) reducing
the number of infants treated with a second medication.
Design is a randomized, blinded comparison. The comparison is between methadone and morphine
Research Design:
a. Procedures: NAS scoring is currently done on infants meeting the inclusion criteria. NAS
scores are done every 2 hours for 24 hours and then every 4 hours when awake after feeding
for the duration of observation and treatment.
i. NAS scores may indicate more than withdrawal. Conditions such as colic (hypercaloric
formula, transient lactose intolerance), reflux, diaper irritation, prenatal SSRI exposure,
and nicotine withdrawal or baseline irritability may influence the variability of scores.
Decisions based on the NAS scores should take into account these factors for the infant.
b. Emergence of symptom, dosing, and initiation of treatment: Withdrawal significant enough
to warrant consideration for treatment is defined as 2 NAS scores >8. Once this threshold has
been reached and consent obtained, the infant is randomized to treatment arm, stratified for
prenatal exposure to methadone or buprenorphine. Twins will be randomized together to the
same arm. The treatment arms are either: i. Methadone (1 mg/mL) or morphine (1 mg/mL)
administered orally every 4 hours. The following is a dosing guide:
NAS Score Methadone or Morphine 8-12 0.05 mg/kg/dose >13 0.1 mg/kg/dose
1. Maximum dose of methadone or morphine will be 0.2 mg/kg/dose. (NeoFax)
2. Additional doses, 0.05 mg/kg, may be given every 12 hours as needed and added to the
next 24 hour's doses divided every 4 hours, until NAS scores are consistently <8 for 48
hours.
3. If the maximum dose of methadone or morphine is reached and if withdrawal is not
controlled, the infant will be started on clonazepam (0.005 mg/kg/dose q 12h) per
current treatment.
c. Tapering medications: When the infant has NAS scores consistently <8 for 36 hours:
i.The taper will be on a daily basis of 10% of the final maintenance dose. Dosages will
be decreased in a measured amount to maintain NAS scores <8. After the last dose, there
will be a 24 to 36 hour observation period.
d.Non-tolerance of tapering: Non-tolerance of tapering is defined as 2 NAS scores >8
during the 12 hour period prior to the next taper dose: i.The tapering should be stopped
at the current level. ii.If necessary, an extra dose of methadone or morphine can be
given and added to the next day's dose divided into 6 doses. If withdrawal re-emerges
after this dose (2 NAS scores >8), then the maintenance dose should be increased back to
the last level; an extra dose may be given up to 4 to 5 hours after the previous dose.
iii. If an extra dose is not given, the wean schedule can be resumed after 24 hours of
NAS scores <8; when dosing is resumed, the frequency should be changed to every 4 hours
with the same total daily dose.
e. Holding of doses: Methadone or morphine will be held for poor feeding, respiratory
depression, or somnolence at any time in the protocol.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01965704 -
Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women
|
Phase 2 | |
Completed |
NCT03890562 -
Assessing the Effects of Auricular Acupressure on Newborns With NAS
|
N/A | |
Completed |
NCT01958476 -
Improving Outcomes in Neonatal Abstinence Syndrome
|
Phase 3 | |
Active, not recruiting |
NCT01734551 -
NAS Treatment - Opiate Versus Non-Opiate
|
Phase 4 | |
Completed |
NCT00496951 -
Vagal Tone and Neonatal Abstinence Syndrome
|
N/A | |
Completed |
NCT02851303 -
Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome
|
Phase 4 | |
Recruiting |
NCT05226624 -
The Alberta Neonatal Abstinence Syndrome Mother-Baby Care ImprovEmeNT Program
|
N/A | |
Completed |
NCT03670160 -
Clonidine Versus Phenobarbital as Adjunctive Therapy for Neonatal Abstinence Syndrome
|
Phase 2 | |
Not yet recruiting |
NCT04611659 -
Averting NAS Among Opioid-Using Young Women Receiving MAT Using Buprenorphine
|
N/A | |
Completed |
NCT01452789 -
Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome
|
Phase 3 | |
Completed |
NCT04588519 -
tAN to Mitigate Withdrawal Behaviors in Neonates
|
N/A | |
Completed |
NCT02797990 -
Conflict Between Maternal Autonomy and Child Health in Substance-use
|
N/A | |
Completed |
NCT02801331 -
Efficacy and Outcomes of a Non-Pharmacological Intervention for Neonatal Abstinence Syndrome
|
N/A | |
Terminated |
NCT03246243 -
Quantitative Assessment of Sucking for Early Diagnosis of Brain Injury in Infants at High Risk
|
||
Completed |
NCT03567603 -
Sound Processing Changes in Babies With Opioid Exposure
|
||
Recruiting |
NCT06303986 -
Study to Collect Data for Neonatal Abstinence Syndrome (NAS) and Evaluate the Automated Data Collection Process
|
||
Active, not recruiting |
NCT03725332 -
The PATH Home Trial: A Comparative Effectiveness Study of Peripartum Opioid Use Disorder in Rural Kentucky
|
N/A | |
Recruiting |
NCT04983563 -
Actigraphy and Neonatal Abstinence Syndrome of Hospitalized Newborn in Intensive Care Units
|
N/A | |
Completed |
NCT04298853 -
Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome
|
Phase 4 | |
Completed |
NCT02182973 -
Donor Human Milk in Neonatal Abstinence Syndrome
|